Masato Bingo

Masato Bingo

Auto-generated profile, based on publicly available information

Masato Bingo

Tokyo Med Univ Hosp, Lab Med, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
RSRyoko Sekiya
Ryoko Sekiya
TMTakashi Muramatsu
Takashi Muramatsu
AIAkito Ichiki
Akito Ichiki
YCYushi Chikasawa
Yushi Chikasawa
MBMasato Bingo
Masato Bingo
EKEi Kinai
Ei Kinai
Treatment with tenofovir alafenamide fumarate (TAF) is associated with body weight gain. However, little or no information is available on this issue in Asian populations. This single-center retrospective study included Japanese people living with HIV (PLWH) who satisfied the following criteria; 1) switching from TDF to TAF after HIV-suppression, 2) follow-up for ≥2 years while on TDF and TAF, and 3) no switching of the third antiretroviral agent. Changes in annual body weight and lipid profiles were compared between the TDF and TAF periods. Of 328 patients, dolutegravir (DTG) was used in 118 PLWH. Overall, no significant difference in weight gain was observed between TDF and TAF (0.76 vs. 0.9 kg/year, p = 0.331). In TAF-period, younger (<50 years of age) group showed significantly greater weight gain than older group (1.03 vs. 0.12 kg/year, p = 0.037). In DTG group, weight gain was larger in TAF-period (0.74 vs. 1.31 kg/year, p = 0.046), especially in younger subgroup (1.43 kg/year) compared with older one (-0.12 kg/year). Multivariate regression analysis showed that TAF was not associated with weight gain (estimates 0.201, p = 0.170) except for DTG group, whereas young age was associated with weight gain in all subjects (estimates -0.033/1 year older, p < 0.001), DTG, RAL, and EFV groups. In Japanese PLWH, annual body weight change was comparable in TDF- and TAF-period, while TAF plus DTG correlated with weight gain. Since young age was a key determinant of weight change, careful interpretation is needed for TAF-associated weight gain.

10 April 2025 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
TATakafumi Akimoto
Takafumi Akimoto
HIHiroshi Inaba
Hiroshi Inaba
SOSoichi Ogishima
Soichi Ogishima
KKKazuki Kumada
Kazuki Kumada
AMAyano Mitsuhashi
Ayano Mitsuhashi
EKEi Kinai
Ei Kinai
• Analysis of the Japanese genome database showed no firm association between VWF pathogenic variants and phenotypic expression. • Estimating VWD prevalence directly based on the variant allele frequencies risks overestimation.

17 October 2023 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
KSKeiko Shinozawa
Keiko Shinozawa
KNKenji Niiya
Kenji Niiya
SFSeiichi Fujimoto
Seiichi Fujimoto
MBMasato Bingo
Masato Bingo
KFKatsuyuki Fukutake
Katsuyuki Fukutake
EKEi Kinai
Ei Kinai
Hemophilia carriers occasionally present with bleeding tendency due to skewed inactivation of normal F8 carrying X chromosome. Can extreme skewing of X-chromosome inactivation (XCI) with trisomy X cause low factor (F) VIII activity and bleeding in a hemophilia carrier?. A young female with low FVIII activity (2 IU/dL), who presented with history of frequent bleeding and F8 variant, NP_000123.1:p.(Arg1800His), was identified. The mother was also confirmed genetically as hemophilia carrier. Karyotype was 47, XXX, multiplex ligation-dependent probe amplification for aneuploidy in the family identified trisomy X only in the index case. Digital polymerase chain reaction using leucocytes, urine, and oral mucosa identified one maternal F8 variant carrying and 2 wild-type F8 carrying X chromosomes, but it detected no somatic mosaicisms. Methylation-sensitive-HpaII-polymerase chain reaction assay showed predominantly activated maternal and 2 fully inactivated paternal X chromosomes. The XCI patterns using tissues of different developmental origins showed extremely skewed XCI. Extreme skewing of XCI can occur even in hemophilia carriers with trisomy X, conferring frequent bleeding and low FVIII activity.

22 October 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
KIKenichi Ikegaya
Kenichi Ikegaya
TMTakashi Muramatsu
Takashi Muramatsu
RSRyoko Sekiya
Ryoko Sekiya
YSYusuke Sekine
Yusuke Sekine
YHYuko Harada
Yuko Harada
EKEi Kinai
Ei Kinai
Background: The two-drug regimen of dolutegravir/lamivudine (DTG/3TC) is currently an optional antiretroviral therapy (ART). Despite its reported advantages on body weight and lipid profile, the same effects have not yet been reported for Asian population. Methods: We conducted a single-center retrospective study involving Japanese people living with HIV (PLWH). They were divided into four groups: those who had received abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) and continued the same (ABC-ON group) or switched to DTG/3TC (ABC-OFF group), those who had received tenofovir alafenamide fumarate/emtricitabine/dolutegravir (TAF/FTC/DTG) and continued the same (TAF-ON group) or switched to DTG/3TC (TAF-OFF group). We compared changes in viral load, CD4* cell count, CD4*/ CD8* ratio, body weight, BMI, lipid profiles, estimated glomerular filtration rate (eGFR), and fibrosis index based on four factors (FIB4-index) between the pre-switch and post-switch period. Results: Of the 541 PLWH on DTG-based ART, 165, 94, 264 and 18 constituted the ABC-ON, ABC-OFF, TAF-ON, and TAF-OFF groups, respectively. Neither viral rebound nor CD4+decline was observed in the post-switch period in all groups. Multivariate analysis showed significant reduction in total cholesterol, LDL-C and HDL-C in the ABC-OFF group (-6.280,-6.957 and-2.268, p = 0.040, 0.012 and 0.022, respectively), but not in the TAF-OFF group (-3.000, 6.708 and 0.046, p = 0.607, 0.276 and 0.983, respectively). No significant changes were observed in body weight, eGFR, or FIB4-index at 72 weeks after the discontinuation of ABC or TAF. Conclusions: Switching from ABC/3TC/DTG to DTG/3TC lowered lipids significantly, but not with TAF/FTC/ DTG. Neither switch affected body weight or other markers.

30 September 2026 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RSRyoko Sekiya
Ryoko Sekiya
TITatsuya Inukai
Tatsuya Inukai
MYMihoko Yotsumoto
Mihoko Yotsumoto
YYYuko Yamada
Yuko Yamada
SKShun Kaneko
Shun Kaneko
SNShigeki Nakamura
Shigeki Nakamura

10 August 2024 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
MBMasato Bingo
Masato Bingo
KFKatsuyuki Fukutake
Katsuyuki Fukutake
KTKanae Togo
Kanae Togo
LXLinghua Xu
Linghua Xu
JAJosé Maria Jimenez Alvir
José Maria Jimenez Alvir
TKToshiyuki Karumori
Toshiyuki Karumori
Background Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity. Objective To determine amounts of clotting factor concentrates (CFCs) and emicizumab dispensed and associated healthcare expenditures in Japanese patients with haemophilia A. Methods This retrospective, non-interventional, observational study analysed data from 2016 to 2020 from a large-scale, hospital-based administrative database. Patients had haemophilia A without inhibitors and ≥ 2 prescriptions of the same CFC or emicizumab. Results In total, 974 patients with haemophilia A (median age, 30.0 years; median follow-up, 3.7 years) were included. Outpatient use of EHL rFVIII and emicizumab increased, although pdFVIII/SHL rFVIII were still used over the study. Median annual total healthcare expenditures/patient increased from ¥9,200,230 in 2016 to ¥19,748,221 in 2020. Overall, the median annual drug expenditure/patient increased from ¥8,723,120 in 2016 to ¥18,051,689 in 2020. Drug expenditure was highest with emicizumab, with an increase in median annual expenditure/patient from 2018 (n = 4, ¥26,030,206) to 2020 (n = 107, ¥45,430,408). Overall, 233 patients (23.9%) switched from an SHL to an EHL product. Although amounts of FVIII prescribed increased in the 3 months after switching, overall, there was no noticeable difference before and after switching. Median total healthcare and FVIII product expenditures increased following switching. Conclusions Prescribing of EHL products increased over the study and healthcare expenditures increased for patients who switched from SHL to EHL rFVIII products.